Sage Therapeutics - SAGE, is currently in phase 3 for unmet need (SRSE) with drug SAGE-547. SRSE is a rare neurological condition, and a sub-type of Status Epilepticus (SE), which is a prolonged seizure. A diagram from this link explains the stages. The Treatment of Super-refractory Status Epilepticus.
Click to Enlarge
SAGE Therapeutics has a Special Protocol Assessment (SPA) with the FDA for this phase 3 clinical trial. The company mentioned, that Refractory Status Epilepticus (RSE) has up to 50% response rate, and that (SRSE) has approximately 35% response rate. The trial should complete first half of 2017. Thank you for reading.
